Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

被引：15
|
作者：
Lee, J.
Hirsh, V.
Park, K.
Qin, S.
Blajman, C. R.
Perng, R.
Emerson, L.
Langmuir, P. B.
Manegold, C.
机构：
[1] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[2] McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] 81 Hosp Chinese Peoples Liberat Army, Nanjing, Jiangsu, Peoples R China
[5] Isis Ctr Especializado, Rosario, Santa Fe, Argentina
[6] Vet Gen Hosp, Taipei, Taiwan
[7] AstraZeneca, Loughborough, Leics, England
[8] AstraZeneca, Wilmington, DE USA
[9] Univ Med Ctr, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
    Lee, Jin Soo
    Hirsh, Vera
    Park, Keunchil
    Qin, Shukui
    Blajman, Cesar R.
    Perng, Reury-Perng
    Chen, Yuh-Min
    Emerson, Laura
    Langmuir, Peter
    Manegold, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1114 - 1121
  • [2] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [4] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [6] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
    Ellis, Peter Michael
    Liu, Geoffrey
    Millward, Michael
    Perrone, Francesco
    Shepherd, Frances A.
    Sun, Sophie
    Cho, Byoung Chul
    Morabito, Alessandro
    Stockier, Martin R.
    Wierzbicki, Rafal
    Cohen, Victor
    Blais, Normand
    Sangha, Randeep S.
    Favaretto, Adolfo G.
    Kang, Jin Hyoung
    Wilson, Carolyn F.
    O'Connell, Joseph
    Ding, Keyue
    Goss, Glenwood D.
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Eberhardt, W. E. E.
    Johnson, B. E.
    Sun, Y.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Tada, H.
    Kennedy, S.
    Herbst, R. S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 505 - 505
  • [9] Vandetanib versus erlotinib in patients with previously treated advanced NSCLC: a randomized, double-blind phase III trial (ZEST)
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S358
  • [10] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
12345